Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | RB1 K240Sfs*22 TP53 R248W |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03360721 | Phase II | Abiraterone + Apalutamide + Prednisone | Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients | Suspended | USA | 0 |
NCT04129151 | Phase II | Ganitumab + Palbociclib | Palbociclib + Ganitumab In Ewing Sarcoma | Active, not recruiting | USA | 0 |
NCT03356223 | Phase II | Abemaciclib | Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL) | Recruiting | FRA | 0 |
NCT01976169 | Phase I | Ado-trastuzumab emtansine + Palbociclib | Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) | Completed | USA | 0 |
NCT02059213 | Phase II | Goserelin Palbociclib Bicalutamide Leuprolide | A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer | Completed | USA | 0 |
NCT04469764 | Phase II | Abemaciclib + Anastrozole Abemaciclib + Letrozole Abemaciclib | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recruiting | USA | 0 |
NCT04388852 | Phase I | DS-3201b + Ipilimumab | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Recruiting | USA | 0 |
NCT02873975 | Phase II | Prexasertib | A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency | Active, not recruiting | USA | 0 |
NCT04116541 | Phase II | Alectinib Cabozantinib Ribociclib + Siremadlin | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
NCT04592237 | Phase II | Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Recruiting | USA | 0 |
NCT04412629 | Phase II | Cabozantinib | Cabozantinib in High Grade Neuroendocrine Neoplasms | Recruiting | USA | 0 |
NCT03834740 | Phase I | Everolimus + Ribociclib | A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection | Active, not recruiting | USA | 0 |
NCT03567642 | Phase I | Carboplatin + Etoposide + Osimertinib Cisplatin + Etoposide + Osimertinib | A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers | Recruiting | USA | 0 |
NCT04391595 | Phase I | Abemaciclib + LY3214996 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | Recruiting | USA | 0 |
NCT03434262 | Phase I | Ribociclib + Trametinib Filgrastim + Gemcitabine + Ribociclib Ribociclib + Sonidegib | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | Recruiting | USA | 0 |
NCT04471974 | Phase II | Enzalutamide + Pembrolizumab + ZEN-3694 | ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT04926181 | Phase II | Apalutamide + Cetrelimab | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | Recruiting | USA | 0 |
NCT04074785 | Phase I | Abemaciclib + Bevacizumab | Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6 | Active, not recruiting | USA | 0 |
NCT04432454 | Phase II | Abemaciclib + Lasofoxifene | Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII) | Active, not recruiting | USA | 0 |
NCT02546661 | Phase I | AZD9150 + Durvalumab Durvalumab + Selumetinib AZD4547 Durvalumab + Olaparib Durvalumab AZD4547 + Durvalumab Durvalumab + Vistusertib Adavosertib + Durvalumab | Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY) | Active, not recruiting | USA | FRA | ESP | CAN | 1 |
NCT02933736 | Phase 0 | Ribociclib | Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients | Recruiting | USA | 0 |
NCT04555837 | Phase Ib/II | Alisertib + Pembrolizumab | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | Recruiting | USA | 0 |
NCT04010357 | Phase II | Abemaciclib | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | Recruiting | USA | 0 |
NCT02981940 | Phase II | Abemaciclib | A Study of Abemaciclib in Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
NCT04118036 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib + Pembrolizumab In Glioblastoma | Withdrawn | USA | 0 |
NCT02599363 | Phase I | Paclitaxel + Ribociclib | A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer | Active, not recruiting | USA | 0 |
NCT02255461 | Phase I | Palbociclib | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | Terminated | USA | 0 |
NCT03781960 | Phase II | Abemaciclib + Nivolumab | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | Active, not recruiting | USA | 0 |
NCT01522989 | Phase I | Fluorouracil + Oxaliplatin + Palbociclib | PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies | Unknown status | USA | 0 |
NCT01356628 | Phase II | Palbociclib | A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer | Active, not recruiting | USA | 0 |
NCT02030483 | Phase I | Palbociclib Dexamethasone Lenalidomide | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma | Terminated | USA | 0 |
NCT03110744 | Phase II | Palbociclib | CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601) | Recruiting | DEU | 0 |
NCT03355794 | Phase I | Everolimus + Ribociclib | A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) | Active, not recruiting | USA | 0 |
NCT03114527 | Phase II | Everolimus + Ribociclib | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | Recruiting | USA | 0 |
NCT04040205 | Phase II | Abemaciclib | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | Recruiting | USA | 0 |
NCT03130439 | Phase II | Abemaciclib | Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | 1 |
NCT03526250 | Phase II | Palbociclib | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | Recruiting | USA | 1 |
NCT02524119 | Phase II | Ribociclib | LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001) | Terminated | USA | 0 |
NCT04316169 | Phase I | Abemaciclib + Anastrozole + Hydroxychloroquine Abemaciclib + Fulvestrant + Hydroxychloroquine Abemaciclib + Hydroxychloroquine Abemaciclib + Hydroxychloroquine + Letrozole | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT02555189 | Phase Ib/II | Ribociclib Enzalutamide | Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression | Recruiting | USA | 0 |
NCT03535506 | Phase II | Palbociclib | Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery (WI223281) | Recruiting | USA | 0 |
NCT02334527 | Phase II | Palbociclib | Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy | Terminated | USA | 0 |
NCT03641313 | Phase II | Berzosertib + Irinotecan | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | Recruiting | USA | 0 |
NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Recruiting | USA | 0 |
NCT03144804 | Phase II | Lamivudine | A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04155840 | Phase II | Bendamustine + Copanlisib + Rituximab | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Terminated | USA | 0 |
NCT01097278 | Phase 0 | Cholecalciferol | S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer | Completed | USA | 0 |
NCT04049539 | Phase II | CPX-351 | Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction | Unknown status | USA | 0 |
NCT04778397 | Phase III | Cytarabine + Idarubicin Azacitidine + Venetoclax Azacitidine + Hu5F9-G4 Cytarabine + Daunorubicin | Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2) | Recruiting | USA | FRA | 3 |
NCT04169737 | Phase II | Acalabrutinib + Obinutuzumab + Venetoclax | Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT04293094 | Phase I | AMG 650 | Study of AMG 650 in Adult Participants With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | CAN | BEL | 2 |
NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Recruiting | CAN | 0 |
NCT03668340 | Phase II | Adavosertib | AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | Recruiting | USA | 0 |
NCT01339871 | Phase I | Vorinostat Pazopanib | Phase I Study of Pazopanib and Vorinostat | Completed | USA | 0 |
NCT04493138 | Phase Ib/II | Azacitidine + Quizartinib | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | Recruiting | USA | 0 |
NCT04214860 | Phase I | APR-246 + Azacitidine + Venetoclax | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies | Completed | USA | 0 |
NCT03734198 | Phase II | Daratumumab + Ibrutinib | Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53) | Recruiting | FRA | 0 |
NCT03931291 | Phase II | APR-246 + Azacitidine | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant | Completed | USA | 0 |
NCT03745716 | Phase III | APR-246 + Azacitidine Azacitidine | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | Active, not recruiting | USA | FRA | 0 |
NCT04708054 | Phase II | Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax | Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04485260 | Phase Ib/II | KRT-232 + Ruxolitinib | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | Recruiting | USA | ITA | FRA | ESP | DEU | 4 |
NCT04419389 | Phase Ib/II | Acalabrutinib + APR-246 APR-246 + Rituximab + Venetoclax | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | Active, not recruiting | USA | 0 |
NCT05218499 | Phase II | BI 907828 Doxorubicin | Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | Recruiting | ESP | CAN | BEL | 1 |
NCT02576444 | Phase II | Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib | OLAParib COmbinations (OLAPCO) | Active, not recruiting | USA | 0 |
NCT03365661 | Phase II | ALT-803 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | Withdrawn | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT03836261 | Phase III | Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab Acalabrutinib + Venetoclax Acalabrutinib + Obinutuzumab + Venetoclax | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 23 |
NCT04908228 | Phase II | Ibrutinib + Obinutuzumab | Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL | Recruiting | ITA | 0 |
NCT04146038 | Phase II | Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | Recruiting | USA | 0 |
NCT03732352 | Phase II | Osimertinib | 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT03462719 | Phase III | Chlorambucil + Obinutuzumab Ibrutinib + Venetoclax | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Active, not recruiting | USA | FRA | ESP | CAN | BEL | 9 |
NCT05027867 | Phase II | KRT-232 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Recruiting | USA | FRA | ESP | 1 |
NCT02275039 | Phase I | MVAp53 Gemcitabine | p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Completed | USA | 0 |
NCT02343172 | Phase Ib/II | Ribociclib + Siremadlin | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | Completed | FRA | ESP | DEU | CAN | 2 |
NCT02629809 | Phase II | Cyclophosphamide + Fludarabine + Ibrutinib + Obinutuzumab Ibrutinib + Obinutuzumab Ibrutinib | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03945721 | Phase I | Niraparib | A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients | Recruiting | USA | 0 |
NCT03781986 | Phase Ib/II | APG-115 | APG-115 in Salivary Gland Cancer Trial | Recruiting | USA | 0 |
NCT01027416 | Phase I | Tamoxifen | Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients | Completed | USA | 0 |
NCT01357161 | Phase II | Carboplatin Adavosertib Paclitaxel | A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | Completed | 0 | |
NCT05180695 | Phase Ib/II | Pazopanib + Siremadlin | HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC) | Recruiting | FRA | 0 |
NCT04435691 | Phase Ib/II | Azacitidine + Hu5F9-G4 + Venetoclax | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03844815 | Phase I | Decitabine + Venetoclax | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05156268 | Phase II | Olaparib + Pembrolizumab | A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Recruiting | USA | 0 |
NCT04010968 | Phase II | Ibrutinib + Venetoclax Cyclophosphamide + Fludarabine + Rituximab | Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC) | Active, not recruiting | FRA | 0 |
NCT03932643 | Phase I | ONC201 | ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant | Recruiting | USA | 0 |
NCT04113616 | Phase Ib/II | KRT-232 Decitabine + KRT-232 Cytarabine + KRT-232 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 6 |
NCT04660045 | Phase II | Acalabrutinib | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Withdrawn | USA | 0 |
NCT02299141 | Phase I | Nintedanib | Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03204188 | Phase II | Fludarabine + Ibrutinib + Pembrolizumab | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT04659616 | Phase I | Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT01760525 | Phase I | CGM097 | A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors | Completed | USA | FRA | DEU | 2 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) | Recruiting | USA | ESP | DEU | CAN | BEL | 2 |
NCT03128879 | Phase II | Ibrutinib + Venetoclax | Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Recruiting | USA | 0 |
NCT04734990 | Phase Ib/II | Azacitidine + Seclidemstat | Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT04285567 | Phase III | Obinutuzumab + Venetoclax Bendamustine + Rituximab Cyclophosphamide + Fludarabine + Rituximab | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO) | Recruiting | USA | ITA | FRA | ESP | 1 |
NCT05275439 | Phase I | Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Recruiting | USA | 0 |
NCT03613532 | Phase I | Busulfan + Fludarabine + Venetoclax | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN | Recruiting | USA | 0 |
NCT02642042 | Phase II | Docetaxel + Trametinib | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT05008055 | Phase II | Capivasertib | Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL) | Recruiting | USA | FRA | ESP | CAN | 3 |
NCT03047993 | Phase Ib/II | Azacitidine + Telaglenastat | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03383575 | Phase II | Azacitidine + Enasidenib Enasidenib | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT04159155 | Phase II | Carboplatin + Cisplatin + Paclitaxel Carboplatin + Niraparib + Paclitaxel Carboplatin + Paclitaxel | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer (CAN-STAMP) | Recruiting | CAN | 0 |
NCT04510584 | Phase II | Atezolizumab + Bevacizumab | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | Recruiting | CAN | 0 |
NCT02301156 | Phase III | Ibrutinib + Ublituximab Ibrutinib | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | Completed | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02098343 | Phase Ib/II | Carboplatin + Doxorubicin APR-246 + Carboplatin + Doxorubicin | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | Completed | USA | FRA | ESP | DEU | BEL | 3 |
NCT04022876 | Phase I | ALRN-6924 + Carboplatin + Pemetrexed Disodium ALRN-6924 + Topotecan Carboplatin + Pemetrexed Disodium | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | Recruiting | USA | ITA | ESP | DEU | 3 |
NCT04190550 | Phase I | Cytarabine + Idarubicin + KRT-232 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04634877 | Phase III | Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 20 |
NCT03661307 | Phase Ib/II | Decitabine + Quizartinib + Venetoclax | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT02193152 | Phase I | Pazopanib | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Terminated | USA | 0 |
NCT04722172 | Phase II | Acalabrutinib + Obinutuzumab | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | Recruiting | USA | 0 |
NCT03063203 | Phase II | Decitabine | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03072043 | Phase Ib/II | APR-246 + Azacitidine | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | Completed | USA | 0 |
NCT04277442 | Phase I | Decitabine + Nivolumab + Venetoclax | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | Suspended | USA | 0 |
NCT04783415 | Phase II | Acalabrutinib + Ublituximab + Umbralisib | Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | Recruiting | USA | 0 |
NCT02042989 | Phase I | Ixazomib + Vorinostat | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | Active, not recruiting | USA | 0 |
NCT03634228 | Phase Ib/II | Cytarabine + Milademetan Tosylate Cytarabine + Milademetan Tosylate + Venetoclax | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02007044 | Phase II | Ibrutinib Ibrutinib + Rituximab | Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03940352 | Phase I | Siremadlin + Venetoclax Sabatolimab + Siremadlin | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | Recruiting | USA | ITA | ESP | DEU | 4 |
NCT02143635 | Phase I | Siremadlin | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Completed | USA | FRA | ESP | DEU | 4 |
NCT03725436 | Phase I | ALRN-6924 + Paclitaxel | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | Recruiting | USA | 0 |
NCT04502394 | Phase Ib/II | Acalabrutinib + KRT-232 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Recruiting | USA | ITA | FRA | BEL | 7 |
NCT02909972 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT01914900 | Phase II | Cisplatin + Docetaxel + Fluorouracil | Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | Completed | ITA | 0 |
NCT04669067 | Phase Ib/II | KRT-232 + TL-895 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Recruiting | USA | ITA | FRA | ESP | DEU | AUT | 2 |
NCT03964233 | Phase I | BI 754091 + BI 754111 + BI 907828 BI 754091 + BI 907828 BI 907828 | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab) | Recruiting | USA | 1 |
NCT03107780 | Phase I | KRT-232 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | Suspended | USA | 0 |
NCT02842125 | Phase I | Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | Terminated | USA | 0 |
NCT03041688 | Phase I | Decitabine + KRT-232 | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine in Patients With Acute Myeloid Leukemia | Suspended | USA | 0 |
NCT02264613 | Phase Ib/II | ALRN-6924 | Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03560882 | Phase I | Atorvastatin | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | Recruiting | USA | 0 |
NCT03714958 | Phase I | Siremadlin + Trametinib | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) | Recruiting | FRA | 0 |
NCT03975387 | Phase Ib/II | ASTX295 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | Recruiting | USA | 0 |
NCT04835584 | Phase Ib/II | Dasatinib + KRT-232 KRT-232 + Nilotinib | KRT-232 and TKI Study in Chronic Myeloid Leukemia | Recruiting | USA | ITA | FRA | ESP | CAN | 3 |
NCT03787602 | Phase Ib/II | Avelumab + KRT-232 KRT-232 | KRT-232 With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma. | Recruiting | USA | ITA | FRA | ESP | DEU | 0 |
NCT04585750 | Phase Ib/II | PC14586 | This Study Will Evaluate PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation | Recruiting | USA | 0 |
NCT02518555 | Phase II | Ibrutinib | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Active, not recruiting | USA | 0 |
NCT01042535 | Phase Ib/II | Ad.p53-DC vaccine + Indoximod | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | Completed | USA | 0 |
NCT03363867 | Phase II | Atezolizumab + Bevacizumab + Cobimetinib | BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON) | Recruiting | 1 | |
NCT02612285 | Phase II | SNX-5422 | Study of SNX-5422 in TP53 Null Cancers | Terminated | USA | 0 |